Bone cancer incidence by morphological subtype: a global assessment
- 465 Downloads
To better understand the relevance of environmental factors to the changing patterns of bone cancer subtypes, we examine the incidence of osteosarcoma (OS), Ewing sarcoma (ES), and chondrosarcoma (CS) using data from cancer incidence in five continents.
Age-specific and age-standardized incidence rates (ASRs) per 100,000 person-years were computed and stratified by country (n = 43), subtype, and sex during 2003–2007. Temporal patterns of ASRs were examined during 1988–2007 (12 countries). Age–period–cohort models were fitted for the USA and UK by subtype.
For most countries, OS represented 20–40 % of all bone cancers, ES < 20 %, while CS proportions varied more considerably. Overall ASRs of bone cancers were 0.8–1.2/100,000 in men and 0.5–1.0 in women (0.20–0.35/100,000 for OS and 0.10–0.30/100,000 for CS in both men and women, and <0.10–0.25/100,000 in men and 0.05–0.25/100,000 in women for ES). The age-specific incidence rates revealed a bimodal peak of OS, one peak of ES in childhood, and a more heterogeneous pattern for CS. The overall bone cancer incidence trends are generally flat, but more heterogeneous for ES and CS. A declining OS incidence was observed in the UK and USA (men), an increase in CS in the UK and USA (female), and an apparent increase in ES, followed by a leveling off in successive US and UK cohorts.
Monitoring bone cancer incidence trends with data assembled from a geographically broader range of registries may generate hypotheses about additional risk factors and ensure that high-risk populations are not overlooked in cancer control efforts.
KeywordsBone Cancer Incidence Worldwide
PCV was supported by an Australian Research Council Future Fellowship (#FT100100511).
Conflict of interest
We declare that we have no conflicts of interest.
- 1.International Agency for Research on Cancer (2013) Cancer incidence in five continents, volume X (electronic version). In: Forman D, Bray F, Brewster D, Mbalawa CG, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J (eds). IARC, Lyon http://ci5.iarc.fr. Accessed 10 Jan 2014
- 10.Blakey K, Feltbower RG, Parslow RC, James PW, Gomez Pozo B, Stiller C, Vincent TJ, Norman P, McKinney PA, Murphy MF, Craft AW, McNally RJ (2014) Is fluoride a risk factor for bone cancer? Small area analysis of osteosarcoma and Ewing sarcoma diagnosed among 0–49-year-olds in Great Britain, 1980–2005. Int J Epidemiol 43:224–234PubMedCentralPubMedCrossRefGoogle Scholar
- 13.Holly EA, Aston DA, Ann DK, Kristiansen JJ (1992) Ewing’s bone sarcoma, paternal occupational exposure, and other factors. Am J Epidemiol 135(2):122–129Google Scholar
- 24.World Health Organization (2000) International classification of diseases for oncology (ICD-0), 3rd ed. In: Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds). World Health Organization, GenevaGoogle Scholar
- 25.Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–57). In: Department of Public Health. Tohoku University of Medicine, Sendai, JapanGoogle Scholar
- 26.Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) (1997) Cancer incidence in five continents, vol. VII (IARC Scientific Publications, No. 143). IARC, Lyon, FranceGoogle Scholar
- 27.Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer incidence in five continents, vol. VIII (IARC Scientific Publications, No. 155). IARC, Lyon, FranceGoogle Scholar
- 28.Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) (2007) Cancer incidence in five continents, vol. IX (IARC Scientific Publications, No. 160). IARC, Lyon, FranceGoogle Scholar
- 31.StataCorp (2011) Stata statistical software: release 12. StataCorp LP, College StationGoogle Scholar
- 33.Cavelaars AE, Kunst AE, Geurts JJ, Crialesi R, Grotvedt L, Helmert U, Lahelma E, Lundberg O, Mielck A, Rasmussen NK, Regidor E, Spuhler T, Mackenbach JP (2000) Persistent variations in average height between countries and between socio-economic groups: an overview of 10 European countries. Ann Hum Biol 27:407–421PubMedCrossRefGoogle Scholar
- 39.McKusick VA (1994) Medical genetics at Johns Hopkins: past, present and future, 11th edn. Johns Hopkins University Press, BaltimoreGoogle Scholar
- 43.Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15:333–342PubMedCrossRefGoogle Scholar
- 47.Kozak K, Adams J, Krejcarek S, Tarbell N, Yock T (2009) A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 74(1):179–186Google Scholar
- 51.Meijer D, Gelderblom H, Karperien M, Cleton-Jansen AM, Hogendoorn PC, Bovee JV (2011) Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res 1:5PubMedCentralPubMedCrossRefGoogle Scholar
- 52.Bray F, Znaor A, Cueva P, Korir A, Swaminathan R, Ullrich A, Wand S, Parkin D (2014) Quality control at the population-based cancer registry. In: Planning and developing population-based cancer registration in low- and middle-income settings (IARC Technical Publication no. 43). International Agency for Research on Cancer (IARC), Lyon, France, pp 21–26Google Scholar